In-Depth Analysis of the ELANE-3 Trial for ESR1+ Breast Cancer

This chapter delves into the Phase III ELANE-3 trial that examines the efficacy of lasofoxifene combined with abemaciclib for ESR1 mutant breast cancer patients. It covers trial design, eligibility, outcomes, and the challenges faced in patient enrollment, particularly regarding prior fulvestrant treatments.